BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodell CB, Ahmed MS, Garris CS, Pittet MJ, Weissleder R. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy. Theranostics 2019;9:8426-36. [PMID: 31879528 DOI: 10.7150/thno.35434] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Yaping W, Zhe W, Zhuling C, Ruolei L, Pengyu F, Lili G, Cheng J, Bo Z, Liuyin L, Guangdong H, Yaoling W, Niuniu H, Rui L. The soldiers needed to be awakened: Tumor-infiltrating immune cells. Front Genet 2022;13:988703. [DOI: 10.3389/fgene.2022.988703] [Reference Citation Analysis]
2 Zhao Y, Bai Y, Shen M, Li Y. Therapeutic strategies for gastric cancer targeting immune cells: Future directions. Front Immunol 2022;13:992762. [DOI: 10.3389/fimmu.2022.992762] [Reference Citation Analysis]
3 Ali DA, Mehanna MM. Role of lignin-based nanoparticles in anticancer drug delivery and bioimaging: An up-to-date review. Int J Biol Macromol 2022;221:934-53. [PMID: 36089088 DOI: 10.1016/j.ijbiomac.2022.09.007] [Reference Citation Analysis]
4 Yang Y, Zhao T, Chen Q, Li Y, Xiao Z, Xiang Y, Wang B, Qiu Y, Tu S, Jiang Y, Nan Y, Huang Q, Ai K. Nanomedicine Strategies for Heating “Cold” Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC. Advanced Science. [DOI: 10.1002/advs.202202797] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Huang L, Ge X, Liu Y, Li H, Zhang Z. The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy. Pharmaceutics 2022;14:1228. [PMID: 35745800 DOI: 10.3390/pharmaceutics14061228] [Reference Citation Analysis]
6 Xiao T, Zhu J, Jia L, Che H, Liu J, Deckers J, van Hest JCM, Shi X. Injectable alginate hydrogels for synergistic tumor combination therapy through repolarization of tumor-associated macrophages. J Control Release 2022:S0168-3659(22)00320-0. [PMID: 35660633 DOI: 10.1016/j.jconrel.2022.05.049] [Reference Citation Analysis]
7 Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol 2022;15:61. [PMID: 35585567 DOI: 10.1186/s13045-022-01282-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
8 Lucas K, Oh J, Hoelzl J, Weissleder R. Cellular point-of-care diagnostics using an inexpensive layer-stack microfluidic device. Lab Chip 2022. [PMID: 35514273 DOI: 10.1039/d2lc00162d] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yin W, Qian S. Delivery of cisplatin and resiquimod in nanomicelles for the chemoimmunotherapy of ovarian cancer. Cancer Nano 2022;13. [DOI: 10.1186/s12645-021-00094-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu Y, Geng Y, Yue B, Lo PC, Huang J, Jin H. Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment. Front Immunol 2021;12:832942. [PMID: 35111169 DOI: 10.3389/fimmu.2021.832942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Haegebaert RM, Kempers M, Ceelen W, Lentacker I, Remaut K. Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer. European Journal of Pharmaceutics and Biopharmaceutics 2022;172:16-30. [DOI: 10.1016/j.ejpb.2022.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kumari N, Choi SH. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-022-02272-x] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
13 Khalifa AE, Ghoneim AI. Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19. Curr Res Pharmacol Drug Discov 2021;2:100068. [PMID: 34870161 DOI: 10.1016/j.crphar.2021.100068] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Keita H. Adamantane-Functionalized Phthalimide Scaffold: Pathways to Supramolecular Interactions and Drug Discovery. Organics 2021;2:388-94. [DOI: 10.3390/org2040022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhuo Z, Wang J, Luo Y, Zeng R, Zhang C, Zhou W, Guo K, Wu H, Sha W, Chen H. Targeted extracellular vesicle delivery systems employing superparamagnetic iron oxide nanoparticles. Acta Biomater 2021;134:13-31. [PMID: 34284151 DOI: 10.1016/j.actbio.2021.07.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
16 Soni SS, Rodell CB. Polymeric materials for immune engineering: Molecular interaction to biomaterial design. Acta Biomater 2021;133:139-52. [PMID: 33484909 DOI: 10.1016/j.actbio.2021.01.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
17 Figueiredo P, Lepland A, Scodeller P, Fontana F, Torrieri G, Tiboni M, Shahbazi MA, Casettari L, Kostiainen MA, Hirvonen J, Teesalu T, Santos HA. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy. Acta Biomater 2021;133:231-43. [PMID: 33011297 DOI: 10.1016/j.actbio.2020.09.038] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 30.0] [Reference Citation Analysis]
18 Chen S, Qin F, Wang M, Wei Y, Qian Z, Wei X. Nanoparticles targeting tumor-associated macrophages: A novel anti-tumor therapy. Nano Res 2022;15:2177-95. [DOI: 10.1007/s12274-021-3781-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Lee SY, Jeon SI, Sim SB, Byun Y, Ahn CH. A supramolecular host-guest interaction-mediated injectable hydrogel system with enhanced stability and sustained protein release. Acta Biomater 2021;131:286-301. [PMID: 34246803 DOI: 10.1016/j.actbio.2021.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
20 Yang Y, Guo J, Huang L. Tackling TAMs for Cancer Immunotherapy: It's Nano Time. Trends Pharmacol Sci 2020;41:701-14. [PMID: 32946772 DOI: 10.1016/j.tips.2020.08.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
21 Bhagchandani S, Johnson JA, Irvine DJ. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. Adv Drug Deliv Rev 2021;175:113803. [PMID: 34058283 DOI: 10.1016/j.addr.2021.05.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
22 Varshney D, Qiu SY, Graf TP, McHugh KJ. Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy. AAPS J 2021;23:90. [PMID: 34181117 DOI: 10.1208/s12248-021-00620-x] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
23 Bolli E, Scherger M, Arnouk SM, Pombo Antunes AR, Straßburger D, Urschbach M, Stickdorn J, De Vlaminck K, Movahedi K, Räder HJ, Hernot S, Besenius P, Van Ginderachter JA, Nuhn L. Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies. Adv Sci (Weinh) 2021;8:2004574. [PMID: 34026453 DOI: 10.1002/advs.202004574] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
24 Kakwere H, Zhang H, Ingham ES, Nura-Raie M, Tumbale SK, Allen R, Tam SM, Wu B, Liu C, Kheirolomoom A, Fite BZ, Ilovitsh A, Lewis JS, Ferrara KW. Systemic Immunotherapy with Micellar Resiquimod-Polymer Conjugates Triggers a Robust Antitumor Response in a Breast Cancer Model. Adv Healthc Mater 2021;10:e2100008. [PMID: 33646600 DOI: 10.1002/adhm.202100008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Soni SS, Alsasa A, Rodell CB. Applications of Macrocyclic Host Molecules in Immune Modulation and Therapeutic Delivery. Front Chem 2021;9:658548. [PMID: 33889565 DOI: 10.3389/fchem.2021.658548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Hingorani DV, Camargo MF, Quraishi MA, Adams SR, Advani SJ. Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs. Pharmaceutics 2021;13:365. [PMID: 33801967 DOI: 10.3390/pharmaceutics13030365] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
27 Muñoz-Garcia J, Cochonneau D, Télétchéa S, Moranton E, Lanoe D, Brion R, Lézot F, Heymann MF, Heymann D. The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis. Theranostics 2021;11:1568-93. [PMID: 33408768 DOI: 10.7150/thno.50683] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
28 Long F, Lin H, Zhang X, Zhang J, Xiao H, Wang T. Atractylenolide-I Suppresses Tumorigenesis of Breast Cancer by Inhibiting Toll-Like Receptor 4-Mediated Nuclear Factor-κB Signaling Pathway. Front Pharmacol 2020;11:598939. [PMID: 33363472 DOI: 10.3389/fphar.2020.598939] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
29 Keshavarz A, Pourbagheri-Sigaroodi A, Zafari P, Bagheri N, Ghaffari SH, Bashash D. Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists. IUBMB Life 2021;73:10-25. [PMID: 33217774 DOI: 10.1002/iub.2412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
30 Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharm Sin B 2020;10:2156-70. [PMID: 33304783 DOI: 10.1016/j.apsb.2020.04.004] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 32.0] [Reference Citation Analysis]
31 He H, Xie C, Lu X. Injectable hydrogels for anti‐tumour treatment: a review. Biosurface and Biotribology 2020;6:59-74. [DOI: 10.1049/bsbt.2020.0020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
32 Koch PD, Pittet MJ, Weissleder R. The chemical biology of IL-12 production via the non-canonical NFkB pathway. RSC Chem Biol 2020;1:166-76. [PMID: 34458756 DOI: 10.1039/d0cb00022a] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Dai X, Lu L, Deng S, Meng J, Wan C, Huang J, Sun Y, Hu Y, Wu B, Wu G, Lovell JF, Jin H, Yang K. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer. Theranostics 2020;10:9332-47. [PMID: 32802195 DOI: 10.7150/thno.47137] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
34 Wang B, Van Herck S, Chen Y, Bai X, Zhong Z, Deswarte K, Lambrecht BN, Sanders NN, Lienenklaus S, Scheeren HW, David SA, Kiessling F, Lammers T, De Geest BG, Shi Y. Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles. J Am Chem Soc 2020;142:12133-9. [PMID: 32524819 DOI: 10.1021/jacs.0c01928] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
35 Dai X, Meng J, Deng S, Zhang L, Wan C, Lu L, Huang J, Hu Y, Zhang Z, Li Y, Lovell JF, Wu G, Yang K, Jin H. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel. Theranostics 2020;10:3049-63. [PMID: 32194854 DOI: 10.7150/thno.42385] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
36 Koch PD, Rodell CB, Kohler RH, Pittet MJ, Weissleder R. Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer Immunotherapy. Cell Chem Biol 2020;27:94-104.e5. [PMID: 31902676 DOI: 10.1016/j.chembiol.2019.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]